A Study of Cabergoline for the Treatment of Cocaine Dependence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-06-30

Study Completion Date

2004-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

NCT01651364

Cocaine Dependence Cocaine Abuse Cocaine Addiction +1 more

COMPLETED PHASE1

Carbamazepine Treatment for Cocaine Dependence - 5

NCT00000191

Cocaine-Related Disorders

COMPLETED PHASE2

Carbamazepine Treatment of Cocaine Dependence - 1

NCT00000242

COMPLETED PHASE2

Carvedilol for Psychostimulant Dependence

NCT01171183

Cocaine Dependence Cocaine Withdrawal

COMPLETED PHASE2

Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6

NCT00000303

Cocaine-Related Disorders

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine-Related Disorders Substance-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cabergoline

Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.

Group Type ACTIVE_COMPARATOR

Cabergoline

Intervention Type DRUG

Placebo

Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

sugar pill manufactured to mimic cabergoline 05mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabergoline

Intervention Type DRUG

Placebo

sugar pill manufactured to mimic cabergoline 05mg tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dostinex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of child-bearing potential using proper method of birth control.